Battelle Memorial Institute – Battelle Memorial Institute is a global science and technology enterprise that develops and commercializes new products and processes for governmental and commercial applications. The world’s largest non-profit independent research and development organization, Battelle has a vast science and technology reach and conducts $4 billion in annual research and development through contract research, laboratory management and technology commercialization. Battelle partners with Ohio State in a number of ways. From collaboration on new therapy-delivery technologies to building the world’s fastest supercomputer, Ohio State and Battelle have joined forces for biomedical research and to create commercial applications for new technology, including nano-technology and biomedical informatics. They are founding partners of the Columbus Business Technology Center.
Intuitive Surgical, Inc. – The Medical Center is one of the two original sites in the world to study the advanced surgical robotics systems developed by Intuitive Surgical, including its daVinci® system. In addition to the studies that led to FDA approval of robotics for heart surgery, Ohio State researchers are perfecting tiny cameras with multiple lenses, which when inserted into a patient’s chest provide a three-dimensional image of the heart.
General Electric Medical Systems – The Ohio State University Medical Center and GE, in a unique corporate -academic partnership – the OSU Advanced Biomedical Imaging Institute – are developing new technologies that provide unprecedented views into the inner workings of the human body and make many invasive diagnostic techniques obsolete.
iMEDD – The principal user of the Ohio MicroMD Laboratory at Ohio State’s Science Village is iMEDD, an emerging drug delivery company that employs microengineering technology to develop improved drug delivery through nanotechnology.
Philips Medical Systems – Ohio State and Case Western Reserve University have teamed with Philips to develop and commercialize one of the first high-power (7-tesla) magnetic resonance imaging systems in the world and to develop breakthrough technologies in molecular imaging used for research on cancer, cardiovascular disease, Alzheimer’s disease and other metabolic diseases of genetic origin.
Siemens - Siemens Medical Solutions in Germany, along with Battelle Memorial Institute and the state of Ohio, is part of a $15 million program to develop innovative strategies and technologies to better prevent, detect and treat lung cancer. The effort is designed to position Ohio as an international leader in fighting the world’s deadliest malignancy. Led by Michael Caligiuri, MD, director of Ohio State’s Comprehensive Cancer Center and CEO of Ohio State’s James Cancer Hospital and Solove Research Institute, the project includes a number of researchers at the University.
State of Ohio– Ohio’s Third Frontier Project aims to establish a high-tech knowledge economy in the state by supporting leading-edge research and development. As part of this project, the Biomedical Research Commercialization Program (BRCP, formerly called the Biomedical Research and Partnership) funds innovative projects with commercial potential in biomedicine and biotechnology. The BRCP has funded several Medical Center programs, including:
- a $6.5 million cardiovascular bioengineering enterprise
- a $1.49 million study on the genetics of gastrointestinal cancer led by Albert de la Chapelle, MD, PhD, and subcontracted with Case Western Reserve University
- a $17.1 million biomedical structural, functional and molecular imaging enterprise led by Michael Knopp, MD, PhD
- a $7.9 million biomedical structural, functional and molecular imaging enterprise (part 2) led by Michael Knopp, MD, PhD
- $24.9 million for the Ohio Research Scholars Program
- $2.99 million for a Molecular Imaging Center as part of the Wright Center of Innovation in Biomedical Imaging
- an $8 million comprehensive program for the prevention, detection and treatment of lung cancer led by Michael Caligiuri, MD
- a $4.25 million commercialization platform for immunotherapeutic treatment of multiple sclerosis led by Caroline Whitacre, PhD
- a $556,834 Stem Cell and Tissue Engineering Institute led by Larry Lasky, MD
Stryker – Stryker Corporation chose Ohio State University Hospital East as one of its showcase sites for construction of its leading-edge, ergonomically sophisticated operating rooms (featuring voice-activated response systems for robotic surgical devices). Ohio State was selected because of its demonstrated commitment to advancing minimally invasive surgical procedures and robotics.
United States Surgical Corporation – U.S. Surgical established the Center for Minimally Invasive Surgery at Ohio State in 1995 with a multimillion dollar donation, which enabled University surgeons to develop and teach the use of advanced laparoscopic and robotic techniques to other health professionals.
In addition to the companies mentioned above, Ohio State’s Medical Center gratefully acknowledges the following companies that made significant research awards to the Medical Center through The Ohio State University Research Foundation during 2008:
- Actelion Clinical Operations, Inc.
- AGA Medical Corp.
- Alcon Labs, Inc.
- Amgen, Inc.
- Arteriocyte, Inc.
- Booz Allen Hamilton, Inc.
- Boston Scientific Corporation
- Bristol-Myers Squibb Company
- Cadence Pharmaceuticals, Inc.
- Cardiokinetix, Inc.
- Carotech Bhd
- Celgene Corporation
- Cepheid
- Columbus NanoWorks, Inc.
- Elan Pharmaceuticals, Inc.
- Genentech, Inc.
- GlaxoSmithKline
- GlobeImmune, Inc.
- Icon Clinical Research, Inc.
- Intermune, Inc.
- International Severity Information Systems
- Jazz Pharmaceuticals, Inc.
- Lorillard Tobacco Company
- Lorus Therapeutics, Inc.
- Medtronic, Inc.
- Merck & Company, Inc.
- MicroMRI, Inc.
- National Football League, Inc.
- Neurologix, Inc.
- Novartis Pharmaceuticals Corporation
- Novo Nordisk Pharmaceuticals
- Pacira Pharmaceuticals, Inc.
- Pfizer, Inc.
- Philips Medical Systems, Inc.
- PPD Development
- PRA International
- Purdue Pharma LP
- Quintiles Transnational Corporation
- Regeneron Pharmaceuticals, Inc.
- SAIC, Inc.
- Sanofi-aventis
- Savacor, Inc.
- SBI Biotech Company, Ltd.
- Schwarz BioSciences, Inc.
- Siemens
- Wyeth Pharmaceuticals, Inc.